Objectives To present historical and contemporary hypotheses on the pathogenesis of
benign prostatic hyperplasia (BPH), and the potential implications for current medical …

Background Little is known about drug adherence in men treated for lower urinary tract
symptoms (LUTS). Benign prostatic hyperplasia (BPH) is one of the causes of LUTS …

A chronic prostatic inflammation seems to play a crucial role in benign prostatic hyperplasia
(BPH) pathogenesis and progression. Therefore, inflammation could represent a new …

Purpose We evaluated the efficacy and safety of add-on treatment with a β 3-adrenoceptor
agonist (mirabegron) for overactive bladder symptoms remaining after α 1-blocker …

A systematic review and meta‐analysis was carried out to evaluate the efficacy and safety of
mirabegron 50 mg and 100 mg in the treatment of storage lower urinary tract …

Background Recent studies showed that the non-adherence to the pharmacological therapy
of patients affected by BPH-associated LUTS increased the risk of clinical progression of …

Benign prostatic hyperplasia and associated lower urinary tract symptoms remain difficult to
treat medically, resulting in hundreds of thousands of surgeries performed annually in …

The standard medical treatment for BPH/LUTS is still based on alpha-blockers, 5ARIs or its
combination. In the future, it is expected that BPH/LUTS treatment will become …

A simple, cheap, sensitive, and time-saving square wave voltammetric (SWV) procedure
using a carbon paste electrode modified with aluminum oxide nanoparticle decorated multi …

Benign prostatic hyperplasia (BPH) is a highly prevalent and costly condition that affects
older men worldwide. Many affected men develop lower urinary tract symptoms, which can …